T
Theravance Biopharma, Inc. (TBPH)
NGM – Real Time Price. Currency in USD
17.63
+0.24 (1.38%)
At close: Jun 26, 2026, 4:00 PM EDT
17.62
-0.01 (-0.06%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
17.63
+0.24 (1.38%)
At close: Jun 26, 2026, 4:00 PM EDT
17.62
-0.01 (-0.06%)
After-hours: Jun 26, 2026, 5:08 PM EDT
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Aine Miller Ph.D. | Senior VP of Development & Head of Ireland Office |
| Mr. Aziz Sawaf C.F.A. | Senior VP & CFO |
| Mr. Brett A. Grimaud Esq. | Senior VP, General Counsel & Secretary |
| Mr. Rick E. Winningham M.B.A. | CEO & Director |
| Mr. Stuart Knight | Senior VP of IT&I and Chief Information Officer |
| Ms. Rhonda F. Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs |
| Ms. Stacy L. Pryce | Senior VP & Chief Strategy Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-23 | 8-K | tm2618538d1_8k.htm |
| 2026-06-12 | 8-K | tm2617876d1_8k.htm |
| 2026-05-07 | 8-K | tm2613884d1_8k.htm |
| 2026-05-07 | 10-Q | tbph-20260331x10q.htm |
| 2026-04-28 | DEF 14A | tm261413-1_def14a.htm |
| 2026-03-30 | 8-K | tm2610626d1_8k.htm |
| 2026-03-23 | 10-K | tbph-20251231x10k.htm |
| 2026-03-19 | 8-K | tm269321d1_8k.htm |
| 2026-03-03 | 8-K | tm267846d1_8k.htm |
| 2026-01-12 | 8-K | tm262807d1_8k.htm |